Santander Aktie

6,40 EUR +0,01 EUR +0,22 %

21.03.2025

STU

6,06 CHF -0,22 CHF -3,46 %

21.03.2025

BRX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.97,48 Mrd. EUR

KGV5,79Div. Rendite3,81%

WKN858872

ISINES0113900J37

SymbolBCDRF

Santander Aktien News

Sortieren:Datum Meistgelesen

14.03.25PR NewswireSanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

28.10.24PR NewswireBeyfortus® immunization to protect infants from RSV has begun

WerbungSantander-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

16.10.24PR NewswireFLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals

26.07.24PR NewswireFluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza

10.07.24PR NewswireSanofi ships U.S. influenza vaccines for the 2024/25 season

12.03.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Banco Santander, S.A. - SAN

08.03.24PR NewswireROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation - SAN

02.03.24PR NewswireSAN INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation - SAN

24.02.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Banco Santander, S.A. - SAN

16.02.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Banco Santander, S.A. - SAN

14.11.23PR NewswireBirchway Tropicana Aims to Bring High Quality Living at Value Pricing to Las Vegas

01.11.23PR NewswireSanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.

13.09.23PR NewswireSanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu

25.07.23PR NewswireSanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact

04.04.23PR NewswireSanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines

27.01.23PR NewswireBetty Jotanovic Is Named President of Chrysler Capital and Auto Relationships at Santander Consumer

18.01.23PR NewswireSanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare

21.12.22PR NewswirePositive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine

16.12.22PR NewswireDupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis

15.12.22PR NewswireDupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis

11.11.22PR NewswireDupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis

11.10.22PR NewswireDupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old

06.10.22PR NewswireSanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes

28.09.22PR NewswireDupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

28.09.22MyDividendsSantander kauft eigene Aktien zurück und erhöht die Zwischendividende

05.09.22PR NewswireLate-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma

12.08.22PR NewswirePublic health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populations

05.08.22PR NewswireSantander Bank Teams Up with Rocket Mortgage to Provide Clients with Digitally Driven Home Loan Experience

03.08.22PR NewswireSanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare

26.07.22PR NewswireSanofi partners with Howard University in an unprecedented pharmacy fellowship program

01.07.22PR NewswireSanofi flu vaccines licensed and approved for 2022-2023 influenza season, including CDC preferred higher-dose vaccines for adults 65+

07.06.22PR NewswireFDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis

02.06.22PR NewswireSantander Consumer USA Brings Cultivate Small Business Program to Dallas in Partnership with Impact Ventures

01.06.22PR NewswireSobi: FDA grants efanesoctocog alfa Breakthrough Therapy designation for haemophilia A

31.05.22PR NewswireFDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis

20.05.22PR NewswireFDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis

26.03.22PR NewswireLate-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis

25.03.22PR NewswireLibtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer

Santander News

Santander News: auf dieser Seite finden Sie alle Santander News und Nachrichten zur Santander Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Santander News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Santander News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.